Complete Response of a Leptomeningeal and Brain Relapse Following Treatment with Pertuzumab Plus Trastuzumab Plus Paclitaxel of a HER2 Positive Breast Cancer

Borrego Manuel Ruiz and Carlos Torrado Martin

Virgen del Rocío University Hospital, Spain

^*Correspondance to: Borrego Manuel Ruiz 

 PDF  Full Text Case Report | Open Access

Abstract:

Central nervous system and leptomeningeal disease due to HER2-positive breast cancer has limited treatment options and poor prognosis. A 67-year-old female previously treated because of a localized HER2-positive breast cancer presented to the Emergency Department in December 2019 due to a 3-month history of worsening headaches and diminished sensation in the left facial area. A Magnetic resonance of the brain demonstrated four intracranial lesions and leptomeningeal disease suggestive of disseminated disease. Pertuzumab 840 mg IV day 1 followed by 420 mg and trastuzumab 8 mg/kg IV on day 1 followed by 6 mg/kg IV cycled every 21 days, and weekly paclitaxel 75 mg/m2 IV was performed for 9 months. Clinical and radiological response was achieved and maintained for more than 34 months.

Keywords:

Cite the Article:

Ruiz BM, Martin CT. Complete Response of a Leptomeningeal and Brain Relapse Following Treatment with Pertuzumab Plus Trastuzumab Plus Paclitaxel of a HER2 Positive Breast Cancer. Clin Case Rep Int. 2022; 6: 1271.